Member Info for dactions

Just tried to but RENE and the price offered was 2.068 Now that's a turn up for the books - let's see if it can keep it and move on from there.

I picked up on Olav's point in the last paragraph: "as well as providing ReNeuron with a significant commercial advantage" I think that's the first time I've seen him allude to selling - so good news indeed !!

Topped up again late today - now just 5.045p We'll look back on this as a day for turning - says me hopefully !

"Hold your nerve " couldn't agree more - topped up at 5.1275

Need to keep to facts. There has been no crash from 10p to 5p in a month. There has been a drop from offer price 7p to offer 5.5p though. It has been seen that the placing broker Turner Pope Investments (TPI) Ltd was selling into the market drop. Presumably the initial placing by them wasn't put into firm hands after all and some of them took advantage of private investors initial eagerness to pay over the placing price. Many have said over years that this is a bad practice and not unique to SRON.

I was a LTH in Halo and got out at a little over 16p two years ago when I believe Neil Woodford invested heavily in this company. I've watched from the wings how it fell steadily but remorsely. I'm surprised that it was allowed to mismange itself with such a notable investor. I say mismanage - expanding into areas that then had to be curtailed and sold off cheaply. They have good products and technology - crazy to be in this situation. Only for the brave now.

I did come away from listening to the Michael Hunt interview on RMAT feeling he could have been more energised and give it a more oomph rather than the " we'll be looking at this and do the paperwork and etc etc " . However, I do see the future for Rene - I've listened to medical practioners even within my own extended family network all talking positively of their hopes within their professions both for Stroke and Retinitus Pigmentosis - both of which Rene is active in. Many of us have been too close to it and see only the future but not the brutal stock market reality - so the current share price must be a shock to them and us. I'm glad I'm not Neil Woodford because even if it isn't his money, it represents his future. We're going to come good on this - it's just a case of when, not if !

The Hardman report heading is: Obtala Ltd - A Platform For Growth Having ploughed through their extensive research which was in today's RNS, I can see why Obtala's management is so confident about growing shareholder value. The recent addition of WoodBois shows how limited cash but with 25% financed by OBT shares and which cannot be sold for some years, shows the exciting possibilities of leverage. Hardman's heavily discounted cash flow and after central costs of 30p matched what others have been projecting. None of these projections can be guaranteed, but the WoodBois deal does show how even better projections could be possible. OBT - a share to tuck away whilst literally the assets grow ?

I have topped up again today at 1.8499 So clearly all the red deals are anything but sales. It's certainly uncomfortable right now being a LTH of Rene - much could be improved as regards presentation - but we are where we are and I am sure this will turn for the better. Remember, Freddie's list of big backers are mostly in at 5p or near so.

. . . Therapy Designation " ReNeuron to apply for Special Protocol Assessment and Regenerative Medicine Advanced Therapy designation as part of US Phase III clinical trial application in stroke disability " This was the opening statement for today's RNS and if granted will be a significant help in providing us much needed positive news flow. This designation from the US is new and recognises a need to fast-track treatments that show sufficient safety coupled with potential for good to people with conditions facing no hope at present. A good short review on RMAT is here: http://www.biopharminternational.com/regenerative-medicine-advanced-therapy-designation-launches-0

Very good points you make succinctly Freddie. Today's news though is definitely good and bodes well for this the most common form of stroke affecting so very many people.

Some late reporting of good sized buys these past days has hidden the true strength of this share. I can see the bid moving back up to 22p Monday and the outlook continues to look positive..

Here's the Share Prophets commentary to save looking for the link. It doesn't add much to what we already know, other than they like new Chairman Miles Pelham. In that fact, I readily agree when I spoke with him at the London Investor Show. I think he told me his background is Banking-Money markets trading. I'd guess he's late 30s, not brash, a bit of a rough diamond that's becoming very smooth. He's convinced that Obtala is now going places - the Hot Rockets target of 30p is too limited in my opinion. quote - The transformation of Obtala (OBT) under Miles Pelham has continued with the $14.8 million purchase of WoodBois, a leading global trader and producer of sawn timber. Obtala shares, tipped by us at an 8.25p offer and retipped at prices much lower than that now trade at 19.75p-21p but are heading far higher. Woodbois has been profitable for the past 5 years and the deal is immediately cash accretive to the Group. Woodbois owns a 102,000 acre forestry concession in Gabon with a fully operational 24,000m3 sawn capacity sawmill and a 18,000m3 veneer plant opening in 2017. The $14.8 million will be paid in 3 tranches and includes c$4 million in shares so the cash cost is $10.8 million leaving Obtala with roughly the same again still in the kitty so can easily afford the $500,000 of capex needed to upgrade and expand the Woodbois facilities. Indeed the third tranche of $5 million is payable over 5 years so swelling Obtala's available cash but also tying in key Woodbois bosses. With the new equity issued Obtala is valued at c $67 million at the mid price. Its Forestry assets have a proven value of round about that valuation. In oher words the remaining cash and the company's agricultural assets are in for free which is barking. On a sum of the parts basis, allowing nothing for any uplift in forestry which is harsh, Obtala is easily worth 30p per share. The fact that, in Pelham, it has one of the most impressive bosses on AIM at the help should merit a premium rating not the current discount rating. We are way ahead on this share tip but there is more to come. If you can get any stock at up to 20.5p do so - at up to that price this is a buy with a target to sell of 30p+ end quote

Great news. This ties in with the very positive general comments made at the London Investor show. Obviously, this wasn't mentioned specifically but they did allude to having plans for this kind of immediate expansion.

Dibs61 - you may be right that there are delayed sell trades still to show. Closer examination of the trades shown on LSE that some reported as buys are really sales, but even so the volume isn't that great. It's more that the marginal higher rate of sales is persistent and as you say, probably by one seller. This is despite recent positive announcements from RENE. Woodford's stake must be causing them some concern as the placing alone done July 15 which cost them £32.5m now has a book value of only £13m and I presume much of their initial investment was done at or above 3p so the total loss in book value for their RENE stake must be huge. I can't help think that if the top two execs, Olav Hellebo and Michael Hunt held actual shares paid with their own money there might be a change in their marketing attitude. I believe last time it was reported, MH held just 2m shares worth now £40,000 whilst Olav Hellebo had at one time just 669,422 worth now just approx £13,000. Both individuals stakes do not give me any confidence. Initially, for these two, they had various options early one, but all at decent target proices (10p and more) - all of these higher priced ones lapsed (the last ones this year) but they've been replaced by even more substantial options - all at only 1p without an obvious expiration date (unless I've misunderstood) so lacking the real incentive I would have thought that was needed to really incentivise. What to do . . . ?

On the face of it, now should be a great way in compared with the original offer price , but with so little actual trading information it's hard to see what would support the SP even at these levels. I actually paid a premium on the offer price, so fingers really burned - ouch !

With recent substantial subscriptions in at 20p & additional purchases by Board members plus asset valuations substantially far in excess of that, I can't see why you should be so gloomy.

Thanks Freddie for link to Exosomes videos - something I hadn't really understood before even though I'm a long term holder. Makes me understand today's RNS and appreciate Rene's potential better.

Extracted from the Stroke RNS was . . . Meetings with the Japanese regulatory agency ("PDMA") are also ongoing in order to advance our CTX cell therapy candidate for stroke disability in Japan under regulations that offer the potential for conditional marketing approval for cell therapies at an earlier stage of clinical development. Is this a significant move for RENE ? Assuming the product performs, could we get from following this route, at least better market recognition of the company's potential ?

For those who missed it before, here is the link: https://www.v o x m a r k e t s.co.uk/content?id=obt_interview